Cryptococcal meningitis causes significant morbidity and mortality in persons with AIDS. Of 236 AIDS patients treated with amphotericin B plus flucytosine, 29 (12%) died within 2 weeks and 62 (26%) died before 10 weeks. Just 129 (55%) of 236 patients were alive with negative cerebrospinal fluid (CSF) cultures at 10 weeks. Multivariate analyses identified that titer of cryptococcal antigen in CSF, serum albumin level, and CD4 cell count, together with dose of amphotericin B, had the strongest joint association with failure to achieve negative CSF cultures by day 14. Among patients with similar CSF cryptococcal antigen titers, CD4 cell counts, and serum albumin levels, the odds of failure at week 10 for those without negative CSF cultures by day 14 was five times that for those with negative CSF cultures by day 14 (odds ratio, 5.0; 95% confidence interval, 2.2 -10.9). Prognosis is dismal for patients with AIDS-related cryptococcal meningitis. Multivariate analyses identified three components that, along with initial treatment, have the strongest joint association with early outcome. Clearly, more effective initial therapy and patient management strategies that address immune function and nutritional status are needed to improve outcomes of this disease.
Prognosis for patients with AIDS and cryptococcal meningipresent with their first episode of AIDS-related cryptococcal meningitis. A standardized approach to patient management tis is poor with existing therapies [1 -6] . Of those patients treated with amphotericin B or fluconazole alone, 60% -65% has been used since 1986, with mycological results and clinical status monitored and recorded in a centralized database. By fail to have a successful outcome at 10 weeks [4, 7, 8] . Of those patients treated with the combination of amphotericin using such information for this group of patients, we identified those baseline characteristics that have the strongest association B or fluconazole plus flucytosine, 35% -45% fail to have a successful outcome by 10 weeks [4, 7, 8] . Baseline patient with failure to achieve a negative CSF culture by day 14, so that more effective initial therapy and patient management characteristics thought to influence outcome, such as severity of illness, immunologic status, and bone marrow, renal, or liver strategies can be developed. function, have been reported not to be associated with outcome in several small series of patients [2 -5, 9] . Indeed, only hyponatremia and positive extraneural cultures at presentation have Methods been reported to be associated with shortened survival [3] . Furthermore, there have been no reports evaluating the contriPatients bution of initial treatment response to overall outcome, although ú50% of patients fail to have a negative CSF culture Patients seen at the LAC -USC Medical Center for AIDSafter 2 weeks of therapy. related cryptococcal meningitis are either entered into clinical Each year at the Los Angeles County -University of Southtrials or treated with amphotericin B plus flucytosine. Patients ern California Medical Center in Los Angeles, ú50 patients enrolled in clinical trials sign written informed consent in accordance with the Institutional Review Board; patients who refuse participation or who are not eligible for participation in clinical trials are treated and followed up under a general proto-the S-PLUS statistical and graphics software [13, 14] . Model assessment followed the strategies for identifying departures Amphotericin B was administered intravenously daily for 2 from assumptions required for valid use of the logistic regresweeks and then thrice weekly. Between 1986 and 1990, the sion model by using graphical techniques in S-PLUS software dosage during the first 2 weeks was 0.7 mg/(kgrd) by intrave- [13 -15] . nous infusion [7] . Beginning in 1990, the dosage was 0. 3 In the first analysis, the response at day 14 was based on mg/(kgrd) intravenously during the first 2 weeks. All patients CSF culture status and was classified as ''negative'' for a received oral flucytosine in a dosage of 150 mg/(kgrd) and, patient alive at day 14 for whom the most recent CSF culture after the first 2 weeks, amphotericin B at 0.7 mg/kg intravewas negative; the response for all other patients was classified nously thrice weekly [8] . Therapy with amphotericin B and as ''not negative.'' This analysis was based on data for all flucytosine was discontinued, and maintenance treatment with patients starting treatment, regardless of whether a follow-up oral fluconazole (200 -400 mg/d) was started when two succes-CSF specimen was obtained within the first 2 weeks, since the sive CSF cultures were negative [11] .
decision to postpone obtaining a CSF specimen could be related to the patient's clinical status and response. Day 14 was selected as the ''landmark'' for the analysis, since the protocol
Patient Management
guidelines for patient management used this time to change Patients were treated as inpatients for the first 2 weeks.
initial therapy from a daily inpatient schedule to an intermittent Amphotericin B therapy was given at the standard dosage unoutpatient schedule. To allow for the situation where day 14 less the serum creatinine level was ú3.0 mg/dL, at which time fell on a weekend, the day 14 analysis included all CSF samples alternate-day dosing was employed. Flucytosine dosing was obtained after study entry and on or before day 17. Although modified according to renal function. If the platelet count or the initial diagnostic CSF sample may have been obtained on absolute granulocyte count was õ50,000/mm 3 or õ1,000/mm 3 , a weekend, follow-up samples would be obtained only on respectively, the dosage of flucytosine was reduced by 50%.
weekdays. If the platelet count or absolute granulocyte count was
The second analysis included only those patients who sur-õ25,000/mm 3 or õ500/mm 3 , respectively, flucytosine therapy vived beyond day 14. The response for this second analysis was stopped. Otherwise, flucytosine treatment was continued was classified as a ''success'' if the patient was alive at week until the end of amphotericin B use.
10 and the most recent CSF culture was negative; otherwise, the Clinical status and mycological results were assessed every response was classified as a ''failure.'' Week 10 was selected as 2 weeks during therapy. In general, CSF samples were obtained the time for assessment of overall outcome, since the acute every 2 weeks until two successive samples were sterile. Treateffects of CNS infection are more likely to dominate in the ment was classified as a success at week 10 if the patient was short term (õ10 weeks), whereas in a longer term assessment, alive and the most recent CSF culture was negative. Treatment outcome will be influenced by the many types of chronic disfor all other patients was classified as a failure. All baseline ease processes seen in this patient population. and follow-up data and mycological results were recorded in a central database.
Univariate Logistic Regression
The first step in each analysis was to use univariate logistic Mycology regression for each covariate to assess the individual association between the response variable and each covariate considTiters of cryptococcal polysaccharide antigen in serum and ered separately [12, 13, 15] . The covariates considered individ-CSF were measured with use of serial twofold dilutions by ually were dose of amphotericin B treatment, baseline CSF means of the latex agglutination method (Meridian Diagnostics, findings, complete blood cell count, CD4 cell count, and meaCincinnati). Fungal cultures were incubated for 5 weeks before sured parameters of renal and liver function. Mycological feabeing declared negative.
tures included titers of cryptococcal antigen in serum and CSF that were measured by latex agglutination testing, and results
Statistical Analyses
of all fungal cultures. Continuous covariates, such as WBC count and serum albumin level, were included in these analyses The primary objective of the multivariate analyses was to as quantitative covariates, with appropriate transformations, so identify the subset of baseline patient characteristics that tothat the association between response (on a logit scale) and the gether had the strongest joint association with CSF culture covariate was linear (or piecewise linear) as required for valid status at day 14. The second objective was to assess the associaapplication of logistic regression [12, 13, 15] . tion of CSF culture status at day 14 on overall outcome at 10 weeks for patients surviving beyond day 14. Separate multivari-
Missing Data
ate logistic regression analyses were conducted for each of these objectives. These analyses followed the model-building Special attention was required for covariates for which there were missing observations for some patients (e.g., results of strategies outlined by Hosmer and Lemeshow [12] The multivariate analysis based on information for the initial sures were §200 mm of CSF in 28% of patients; a CSF opening 236 patients identified four covariates (CSF cryptococcal antipressure was not recorded for 51% of patients. CSF specimens gen titer, dose of amphotericin B, serum albumin level, and from 10% of the patients were negative by India ink capsule CD4 cell count) that together had the strongest joint association staining; 16% of patients in the high-dose group and 25% in with failure to achieve a negative CSF culture by day 14. The the low-dose group had CSF cryptococcal antigen titers of odds ratios and 95% confidence intervals for the odds ratios §1:16,384 (P Å .06; Wilcoxon rank-sum test).
based on the univariate and the final multivariate logistic analyses are shown in table 3. The P value for each covariate indicates the statistical significance of the additional contribution Toxicity of that covariate, given the joint association of the other three Flucytosine therapy was discontinued within 14 days for 10 covariates in the multivariate logistic regression model. Of the (4%) of the 236 patients, of whom five received high-dose four covariates identified by the multivariate analysis, CSF amphotericin B and five received low-dose amphotericin B.
cryptococcal antigen titer had the strongest association with Flucytosine therapy was discontinued because of thrombocytofailure to achieve a negative CSF culture by day 14. Thus, penia in 4 patients, vomiting in 1, acute renal failure in 1, among patients with similar levels of serum albumin, CD4 cell neutropenia in 1, and unspecified reasons for 3. Continuation counts, and dosages of amphotericin B, the odds of failing of flucytosine therapy after hospital discharge (although preto have a negative CSF culture for those with baseline CSF scribed) was not well documented, thus precluding a detailed cryptococcal antigen titers of §1:1,024 was nine (95% CI, report of flucytosine toxicity after day 14.
3.7 -22.0) times that for patients with baseline CSF cryptococcal antigen titers of £1:16. The dependence of the estimated probability of failing to
Univariate Analysis of Culture Status at Day 14 achieve a negative CSF culture by day 14 on serum albumin level, amphotericin B dosage, and CSF cryptococcal antigen At day 14, 76 (32%) of 236 patients treated with amphoterititer for patients for whom baseline CD4 cell counts were not cin B plus flucytosine had negative CSF cultures; 160 patients assessed is shown in figure 1A . This information for patients (68%) failed to have a negative CSF culture. Of these patients, for whom baseline CD4 cell counts were assessed is shown in 65 had positive CSF cultures, 63 had no CSF samples within figure 1B. Patients most likely to fail to have a negative CSF the first 2 weeks, 29 had died, and 3 were lost to follow-up culture by day 14 had CSF cryptococcal antigen titers of (data not shown). The associations between failure to achieve ú1:512 (figures 1A and 1B, left panels). Patients with the a negative CSF culture by day 14 and each baseline laboratory worst prognosis (estimated probability of failing to have a and CSF finding considered individually in the univariate logisnegative culture by day 14, 85% -95%) within this subgroup tic analyses are shown in table 2. There was a strong linear were those who did not have CD4 cell counts assessed and association between increasing serum cryptococcal antigen tireceived therapy with low-dose amphotericin B (figure 1A, left ters (on a log base 2 scale) and an increasing chance of failing panel). In fact, the only patients in this subgroup who actually to achieve a negative CSF culture by day 14 (on a logit scale) had a negative CSF culture by day 14 were those who had for patients with titers of §1:1,024 (P õ .0001); for those with serum albumin levels of ú3.5 g/dL (figure 1A, left panel). serum cryptococcal antigen titers of õ1:1,024, these titers were Patients with CSF cryptococcal antigen titers of ú1:512 who not associated with culture status at day 14. Of patients who did have CD4 cell counts assessed (figure 1B, left panel) had received therapy with high-dose amphotericin B, 59% failed a somewhat lower probability of failing to have a negative to have a negative CSF culture by day 14 compared with 73% CSF culture by day 14 (70% -90%, low-dose amphotericin B of those who received therapy with low-dose amphotericin B recipients; 60% -80%, high-dose amphotericin B recipients). (P Å .022). CSF leukocyte count (P Å .007), India ink capsule Patients with the lowest (20% -50%) chance of failing to have staining result (P Å .04), and CSF cryptococcal antigen titer a negative CSF culture by day 14 were those who had low (P õ .00001) each had a strong univariate association with CSF cryptococcal antigen titers (£1:16) and CD4 cell counts CSF culture status at day 14.
assessed ( figure 1B, right At 10 weeks, 75 (37%) of these 204 patients did not have a level, CD4 / cell count, India ink capsule staining result, and CSF cryptococcal antigen titer had strong univariate associanegative CSF culture, and 129 (63%) had a successful outcome. Of the 128 patients surviving beyond day 14 who did not have tions with outcome at week 10. The subgroup of patients without a negative CSF culture by a negative CSF culture by day 14, 64 (50%) failed to have a negative CSF culture by 10 weeks, whereas, of 76 patients day 14 included those patients who died within 2 weeks, those patients who survived beyond day 14 for whom the CSF culture surviving beyond day 14 who had a negative CSF culture by day 14, 11 (15%) failed to have a negative CSF culture by 10 was positive, and those patients who survived beyond day 14 but who did not have a follow-up CSF sample obtained within weeks (P õ .0001).
The associations between outcome at week 10 and each the first 2 weeks. The univariate associations between CSF culture status at day 14 and the outcomes at weeks 4, 6, and baseline laboratory and CSF finding considered individually in the univariate logistic regression analyses for the 204 patients 10 are shown in only patients with actual successes at week 10 were those who had serum albumin levels of ú3.5 g/dL (figure 2A, left panel).
* Represents the statistical significance of the additional contribution for
Patients who had the lowest chance of failure (õ10%) at week that covariate given the joint effect of the other three covariates.
10 were those who had baseline CSF cryptococcal antigen titers of £1:2,048, ú60 CD4 / cells/mm 3 , and a negative CSF culture by day 14 (figure 2B, right panel). comes for those patients who did not have a follow-up CSF sample obtained by day 14. The outcome at week 10 was similar for the latter two groups, 49% and 51%, respectively. Discussion Furthermore, a multivariate logistic regression analysis of reOf the initial 236 AIDS patients with cryptococcal meningisults for the 204 patients surviving beyond day 14 was pertis, 45% failed to have a negative CSF culture by week 10. In formed (data not shown) by using a three-level categorization fact, ú25% of these patients died before week 10. These dismal for CSF culture status at day 14. Results of this multivariate results underscore the acute need for improved strategies for analysis showed that the subgroup ''patients with a positive treatment of this patient population, regardless of risk group. CSF culture at day 14'' and ''patients without a follow-up CSF By using information for this group of patients, we identified sample by day 14'' had similar associations with outcome at those baseline characteristics that have the strongest association week 10.
with failure to achieve a negative CSF culture by day 14, so that more effective initial therapy and patient management
Multivariate Analysis of Outcome at Week 10 for Patients
strategies can be developed.
Alive at Day 14
Among patients surviving beyond day 14 who had similar levels of serum albumin, CSF cryptococcal antigen titers, and The multivariate analysis for the 204 patients surviving beyond day 14 identified four covariates that together had the CD4 cell counts, the odds of failure at week 10 for those without a negative CSF culture by day 14 was five times greater strongest joint association with failure at 10 weeks: serum albumin level, CSF cryptococcal antigen titer, CD4 cell count, than that for those with a negative CSF culture by day 14. When patients were unwilling or unable to undergo CSF sampling by and CSF culture status at day 14. The odds ratios and 95% confidence intervals for the odds ratios for these covariates day 14, the prognostic implications were similar. Both patients with positive CSF cultures and those for whom CSF cultures from the univariate and the final multivariate logistic analyses are shown in table 6. The P value for each covariate indicates are not known to be negative had a strikingly higher risk of failing to have a favorable clinical outcome at 10 weeks. the statistical significance of the additional contribution of that covariate, given the joint association of the other three covariMultivariate analysis of the initial 236 patients identified three baseline characteristics that, together with the dose of ates in the final multivariate logistic regression model. Of these four covariates identified by the multivariate analysis, the two amphotericin B, had the strongest joint association with failure to achieve a negative CSF culture by day 14. All patients that had the strongest association with outcome at week 10 were CD4 cell count (OR, 5.2; 95% CI, 1.5 -17.3) and CSF treated according to the protocol before 1990 received highdose amphotericin B; all patients treated thereafter received culture status at day 14 (OR, 5.0; 95% CI, 2.2 -10.9). Among patients with similar levels of serum albumin, CSF cryptococlow-dose. Thus, the effect of amphotericin B dose cannot be distinguished from any changes in patient characteristics assocal antigen titers, and CSF culture status at day 14, the odds of failure at week 10 for those whose baseline CD4 cell counts ciated with time. In fact, in the patient population seen at the Los Angeles County -University of Southern California were not assessed was 5.2 times greater than that for those / 9c5e$$ja09
12-27-98 19:07:25 cidal UC: CID ᮀ Å low-dose amphotericin B therapy and negative CSF culture by ᭺ Å high-dose amphotericin B therapy and negative CSF culture by day 14; day 14; Å low-dose amphotericin B therapy and CSF culture not negative l Å high-dose amphotericin B therapy and CSF culture not negative by day 14;
by day 14. Medical Center, there was a marked decline in the CD4 / cell status at day 14 and because all patients received similar amphotericin B dosages after day 14. count at diagnosis of meningitis over the study period.
A second multivariate analysis, based on information for The first of the important clinical characteristics most strongly associated with outcome is the CSF cryptococcal patients surviving beyond day 14, identified that these same characteristics, together with CSF culture status at day 14, had antigen titer, representing the severity of fungal burden in the CNS. This component might also be measured by semithe strongest joint association with outcome at 10 weeks for patients surviving beyond day 14. These characteristics, CSF quantitative India ink capsule staining of CSF or other parameters of the CSF profile. The last two clinical compocryptococcal antigen titer, serum albumin level, and CD4 cell count, represent three important components of the clinical nents, serum albumin level and CD4 / cell count, represent more general aspects of patient status that reflect the progrescourse for a patient with HIV-associated cryptococcal meningitis. Amphotericin B dose was not among the characteristics sion of HIV infection. We believe that the serum albumin level most probably represents the patient's nutritional stawith the strongest association, most likely because the effects of the initial dose were subsumed with the effect of CSF culture tus. Although several disease processes in addition to nutri-/ 9c5e$$ja09 12-27-98 19:07:25 cidal UC: CID tional status can influence the serum albumin level, these wasting syndrome. However, given the absence of overt liver and kidney dysfunction, the most likely explanation of the role patients had normal liver and renal function. They exhibited little overt liver damage as evidenced by an elevated serum of the serum albumin level in these patients is the failure to absorb appropriate nutrients or gastrointestinal losses of albubilirubin level or prolonged prothrombin time (data not shown), although alterations in transaminase levels were min. It was striking how consistently the serum albumin level correlated with the probability of outcome, even after adjusting common. However, it is possible that occult liver disease such as chronic hepatitis B or C could have been present for the other dominant clinical factors (figures 1 and 2). The third baseline characteristic associated with outcome in and we failed to recognize it.
Overt renal dysfunction, as evidenced by an elevated serum our multivariate analyses was based on the number of CD4 / T lymphocytes. As one of the clinical characteristics associated with creatinine level or proteinuria, was absent, and it seems less likely that occult renal disease was present but unrecognized.
failure to achieve a negative CSF culture by day 14, this covariate was a simple yes/no variable indicating whether the CD4 cell Gastrointestinal complaints and known gastrointestinal pathogens before or during the treatment of cryptococcal meningitis count had been assessed within 1 month before treatment. The CD4 / T lymphocyte count is generally considered to reflect the were not recorded in our database nor was the presence of / 9c5e$$ja09 day 14 may be a very useful biological marker and could be used to make clinical management decisions for individual patients. The CSF culture status at day 14 should be evaluated prospectively for use as an early end point in clinical trials to ''stage'' of HIV-related disease and the degree of immune suppression. The poorer outcome observed for those patients for evaluate new treatment regimens. Although our results alone do not establish that increasing the proportion of patients with whom the CD4 cell counts were not assessed certainly cannot be improved simply by obtaining a current CD4 / T lymphocyte negative CSF cultures at day 14 would automatically translate to a decrease in the proportion of patients without negative count. That these counts were not obtained may reflect the physician's assessment of the overall clinical status of the patient and CSF cultures at 10 weeks, our results certainly demonstrate that failure to achieve a negative CSF culture by day 14 is an the consequent reluctance to request a laboratory test for which the results were not expected to influence decisions regarding indication of a much higher chance of failure at 10 weeks. In this study of 236 patients with AIDS-related cryptococcal patient management. The association of CD4 cell count with outcome at week 10 for patients surviving beyond day 14 was meningitis who were treated with amphotericin B plus flucybased on three subgroupings: ú60 CD4 / cells/mm , and CD4 cell count not assessed. Selecting a potent initial therapeutic regimen is of critical importance, since those patients who respond initially fare so * Represents the statistical significance of the additional contribution for that covariate given the joint effect of the other three covariates. much better than do those who do not. It may be useful to / 9c5e$$ja09
12-27-98 19:07:25 cidal UC: CID ᮀ Å negative CSF culture at day 14 and success at week 10; ᭺ Å CSF culture not negative at day 14 and success at week 10; Å negative CSF culture at day 14 and failure at week 10; l Å CSF culture not negative at day 14 and failure at week 10. ; right panel, ú60 CD4 / cells/mm 3 . The height of each symbol represents the estimated probability of failure at week ten (vertical axis) given a patient's observed serum albumin level (horizontal axis), CSF culture status at day 14, CD4 cell count and CSF cryptococcal antigen titer, which were based on the multivariate logistic model (table 6) . Squares represent patients with negative CSF cultures by day 14. Circles represent patients without a negative CSF culture by day 14. For comparison between the estimated probability of failure (vertical axis) and the observed outcome at week 10, open symbols indicate observed successes at week 10; filled symbols indicate observed failures at week 10. The open symbols have been plotted slightly lower to prevent masking by the filled symbols. Gray horizontal and vertical reference lines have been added to facilitate comparisons among panels.
tosine, nearly 70% failed to have a negative CSF culture by nous therapy rather than change to oral outpatient therapy, as is current practice [17, 18] . day 14. Of these patients, 12% died before day 14, and by 10 weeks, ú25% of the patients had died. Just 55% of the AIDS patients presenting with cryptococcal meningitis were alive at
